Valneva SE (VALN) stock

VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 17, 2026Score 1/30

$5.66−0.10 (-1.74%)

Close on Nov 13, 2026Market cap $491.12MP/E –Yield –

Valneva EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Valneva's EV/EBITDA was 35.5× on Apr 30, 2025.

Period	Period end	Value	Change (pts)
2025	Apr 30, 2025	35.5×	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VALN.

Revenue growth-27.2% · median 25.4%

Gross margin16.4% · median 89.0%

Operating margin-80.5% · median -21.2%

Advertisement
300 × 250

See a number that looks wrong?